The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...

For example, he proposed 25% tariffs on imports from Canada and Mexico ... is the main competition for Lilly's Mounjaro. Novo's obesity drug, Wegovy, is the top rival to Lilly's Zepbound.

Investing.com -- Novo Nordisk 's (NYSE:NVO) (CSE:NOVOb) blockbuster weight-loss drug Wegovy may have difficulty securing approval from Medicare for coverage as a heart disease... In a recent ...

(Reuters) - Four doses of Eli Lilly (NYSE:LLY)'s diabetes drug Mounjaro would remain in tight supply through 2024 due to soaring demand, the U.S. Food and Drug Administration's ...

Market report delivers crucial insights into the market's growth trajectory and the primary revenue drivers anticipated ...